Maia Biotechnology Inc (MAIA)

$1.55 +0.01 (0.65%)
Market Cap 45.86M
Revenue (ttm) 0.00
Net Income (ttm) -23.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 36,700
Avg Vol 123,098
Day's Range N/A - N/A
Shares Out 29.59M
Stochastic %K 68%
Beta 0.38
Analysts Strong Sell
Price Target $14.00

Latest News on MAIA

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

Apr 1, 2025, 8:30 AM EDT - 19 days ago

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

Mar 25, 2025, 8:46 AM EDT - 26 days ago

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

Mar 20, 2025, 9:20 AM EDT - 4 weeks ago

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO

Mar 19, 2025, 11:00 AM EDT - 4 weeks ago

MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

Feb 27, 2025, 8:51 AM EST - 7 weeks ago

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

Feb 26, 2025, 8:47 AM EST - 7 weeks ago

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

Feb 24, 2025, 4:30 PM EST - 7 weeks ago

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

MAIA Biotechnology Announces Private Placement of $2,715,000

Feb 18, 2025, 3:44 PM EST - 2 months ago

MAIA Biotechnology Announces Private Placement of $2,715,000

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

Feb 4, 2025, 8:51 AM EST - 2 months ago

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology to Present at Biotech Showcase 2025

Jan 10, 2025, 9:45 AM EST - 3 months ago

MAIA Biotechnology to Present at Biotech Showcase 2025

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

Dec 19, 2024, 8:47 AM EST - 4 months ago

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

Dec 16, 2024, 8:37 AM EST - 4 months ago

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

MAIA Biotechnology Announces Private Placement of Approximately $950,000

Dec 9, 2024, 6:00 PM EST - 4 months ago

MAIA Biotechnology Announces Private Placement of Approximately $950,000

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

Dec 3, 2024, 8:17 AM EST - 4 months ago

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement

Nov 7, 2024, 8:47 AM EST - 5 months ago

MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement

MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Nov 5, 2024, 9:45 AM EST - 5 months ago

MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

MAIA Biotechnology Announces $2.44 Million Private Placement

Oct 28, 2024, 7:00 PM EDT - 6 months ago

MAIA Biotechnology Announces $2.44 Million Private Placement

MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics

Oct 15, 2024, 8:15 AM EDT - 6 months ago

MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics

MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer

Sep 10, 2024, 6:00 AM EDT - 7 months ago

MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer

MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:30 AM EDT - 8 months ago

MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients

Jul 23, 2024, 10:38 AM EDT - 9 months ago

MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

Jul 23, 2024, 4:11 AM EDT - 9 months ago

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy

Jun 7, 2024, 12:31 PM EDT - 11 months ago

MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy

MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent

Jun 6, 2024, 10:07 AM EDT - 11 months ago

MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent

MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer

Jun 4, 2024, 8:41 AM EDT - 11 months ago

MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer

MAIA Biotechnology to Present at the BIO International Convention 2024

May 17, 2024, 8:37 AM EDT - 1 year ago

MAIA Biotechnology to Present at the BIO International Convention 2024

MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

May 16, 2024, 8:37 AM EDT - 1 year ago

MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement

Apr 30, 2024, 8:08 AM EDT - 1 year ago

MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement

Apr 29, 2024, 8:08 AM EDT - 1 year ago

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement

MAIA Biotechnology Announces $1.00 Million Private Placement

Apr 23, 2024, 8:51 AM EDT - 1 year ago

MAIA Biotechnology Announces $1.00 Million Private Placement

MAIA Biotechnology to Present at Two Investor Conferences in April 2024

Apr 5, 2024, 8:01 AM EDT - 1 year ago

MAIA Biotechnology to Present at Two Investor Conferences in April 2024

MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero

Mar 28, 2024, 3:00 PM EDT - 1 year ago

MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero

MAIA Biotechnology Announces $1.33 Million Private Placement

Mar 26, 2024, 8:01 AM EDT - 1 year ago

MAIA Biotechnology Announces $1.33 Million Private Placement

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement

Mar 22, 2024, 3:00 PM EDT - 1 year ago

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement

MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board

Mar 21, 2024, 3:00 PM EDT - 1 year ago

MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board

MAIA Biotechnology to Participate in the 36th Annual ROTH Conference

Mar 7, 2024, 9:45 AM EST - 1 year ago

MAIA Biotechnology to Participate in the 36th Annual ROTH Conference

MAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting

Mar 6, 2024, 11:04 AM EST - 1 year ago

MAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting

MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients

Mar 6, 2024, 8:48 AM EST - 1 year ago

MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients

MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders

Mar 5, 2024, 8:45 AM EST - 1 year ago

MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

Feb 27, 2024, 10:30 AM EST - 1 year ago

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

Feb 22, 2024, 10:30 AM EST - 1 year ago

MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

Feb 7, 2024, 8:01 AM EST - 1 year ago

MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds

Jan 24, 2024, 7:15 AM EST - 1 year ago

MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds

MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

Jan 17, 2024, 9:00 AM EST - 1 year ago

MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024

Jan 5, 2024, 8:00 AM EST - 1 year ago

MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024

MAIA Biotechnology: Significantly Undervalued With Novel Mechanism And Impressive Early Data

Jan 4, 2024, 9:04 AM EST - 1 year ago

MAIA Biotechnology: Significantly Undervalued With Novel Mechanism And Impressive Early Data

MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

Dec 19, 2023, 7:00 AM EST - 1 year ago

MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering

Nov 17, 2023, 3:52 PM EST - 1 year ago

MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering

MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer

Nov 17, 2023, 9:00 AM EST - 1 year ago

MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer

MAIA Biotechnology Announces $4 Million Registered Direct Offering

Nov 15, 2023, 9:35 AM EST - 1 year ago

MAIA Biotechnology Announces $4 Million Registered Direct Offering